Prometheus’ Lotronex REMS Could Lose Its Sticker Verification Requirement

FDA seeks advisory committee input on options for revising the irritable bowel syndrome drug’s Risk Evaluation and Mitigation Strategy, including eliminating a requirement for paper-based prescriptions and integrating the REMS into electronic pharmacy management systems.